



## **Akari Therapeutics to Present at the H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference**

**BOSTON and LONDON – September 5, 2025** – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the [H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference](#) being held from September 8-10, 2025 in New York, NY.

In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference [website](#).

A [video webcast](#) of the presentation will be accessible for viewing on-demand beginning on Friday, September 5, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the [Presentations](#) page in the [Investors](#) section of the Company's website ([akaritx.com](http://akaritx.com)). The webcast replay will be archived for 90 days following the event.

### **About Akari Therapeutics**

Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The

Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.

For more information about the Company, please visit [www.akaritx.com](http://www.akaritx.com) and connect on [X](#) and [LinkedIn](#).

### **Investor Relations Contact**

JTC Team, LLC  
Jenene Thomas  
908-824-0775  
[AKTX@jtcir.com](mailto:AKTX@jtcir.com)